Optimizing Myelofibrosis Management: Clinical Strategies, Treatment Innovations, and Financial Toxicity Considerations : Episode 10

Advancing Myelofibrosis Treatment: What Lies Ahead

August 28, 2024

By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Opinion

Video

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, looks to the future of myelofibrosis treatment and discusses ongoing research and the evolving therapeutic landscape.

EP: 1.Myelofibrosis Overview: US Incidence, Prognosis, and Patient Presentation

EP: 2.Unmet Needs in Myelofibrosis: Key Challenges in Disease Management

EP: 3.Impact of Myelofibrosis on Quality of Life: Key Clinical Features

EP: 4.Primary Management Goals and Importance of Risk Stratification in Myelofibrosis

EP: 5.JAK Inhibitors and Myelofibrosis Management: A Review of Current Treatments

EP: 6.Key Patient Factors Guiding Myelofibrosis Treatment Selection

EP: 7.Key Outcomes for Monitoring Myelofibrosis Treatment Response

EP: 8.Strategies for Treatment Optimization and Adverse Event Reduction in Myelofibrosis

EP: 9.Understanding Financial Toxicity in Myelofibrosis

Now Viewing

EP: 10.Advancing Myelofibrosis Treatment: What Lies Ahead

EP: 11.K-Cast Written Summary. Optimizing the Management of Myelofibrosis

Video content above is prompted by the following:

What combinations of new and existing therapies are being explored for myelofibrosis?

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!